Austin Px

Oct 7, 2024 | outsourcedpharma.com | Dave Miller |Austin Px |Louis Garguilo

By Dave Miller, PhD, AustinPx Oral solid dose (OSD) formulation development must adhere to common considerations, such as project timelines, facilitating CDMO/client transparency and overcoming regulatory challenges. However, development’s difficulty often is compounded by numerous factors such as API supply constraints, challenging physiochemical properties, poor bioavailability, and/or constrained safe handling requirements, to name just a few.

Apr 8, 2024 | money.mymotherlode.com | Austin Px

Expanding Offerings Enable Faster Timelines and Reduced RiskAustinPx, a leading contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, today announced its acquisition of a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer®, and the STYL’One Nano compaction simulator.

Mar 5, 2024 | money.mymotherlode.com | Austin Px

Scott to Transition to Executive Board Chair AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol™ Technology, and a contract development and manufacturing organization (CDMO), today announced that Elizabeth Hickman, chief business officer, will succeed Tim Scott in January 2025 as president and CEO of AustinPx. Scott has led the company’s new direction as a CDMO since 2022, successfully positioning the company’s leadership as an oral drug delivery dosage form...

Jan 31, 2024 | money.mymotherlode.com | Austin Px

Partnership Strengthens Commercialization Options for AustinPx’s ClientsAustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, and Microsize, a leading active pharmaceutical ingredient enhancement CDMO, today announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol® Technology platform.

May 9, 2023 | money.mymotherlode.com | Austin Px

Additional Capabilities Strengthen CDMO OfferingsAustinPx, a contract development and manufacturing organization (CDMO) specializing in analytical and formulation development services and cGMP manufacturing for small molecule drugs, today announced the expansion of its capabilities to meet industry demand for the Company’s services and expertise.